ZS Pharma (ZSPH) Misses Q3 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. NVDA
4. USO
5. TSLA
6. GNK
7. FNGR
8. PLUR
9. MU
10. ARGX

Go back to ZS Pharma (ZSPH) Misses Q3 EPS by 7c

ZS Pharma Reports Third Quarter 2014 Financial Results and Provides ZS-9 Program Update

November 10, 2014 4:00 PM EST

COPPELL, Texas, Nov. 10, 2014 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today reported financial results for the third quarter ended September 30, 2014 and provided a program update on ZS-9 (sodium zirconium cyclosilicate), the Company's investigational treatment for hyperkalemia.

"During the quarter, we continued to make progress on our clinical development goals, highlighted by the positive top-line results from HARMONIZE, our second Phase 3 trial of ZS-9," said Robert Alexander, Ph.D., chief executive officer of ZS Pharma. "We were pleased... More